<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084122</url>
  </required_header>
  <id_info>
    <org_study_id>FEIV-DC-09</org_study_id>
    <nct_id>NCT01084122</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia</brief_title>
  <official_title>Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of intravenous iron sucrose
      in patients with hip fracture and surgical intervention to prevent perioperative anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the safety and efficacy of intravenous iron
      sucrose in patients with hip fracture and surgical intervention to prevent perioperative
      anemia.

      It will also determine whether intravenous iron sucrose administration improve outcomes as
      Haemoglobin values, transfusional needs, postoperative complications, length of hospital stay
      and cost-effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusional needs</measure>
    <time_frame>1st, 5th day and 1st and 6 th month after surgical intervention.</time_frame>
    <description>Blood transfusion rate in patients over 65 years undergone hip fracture and surgical intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Units of packed cells</measure>
    <time_frame>1st and 5th days, 1st and 6th month after surgical intervention.</time_frame>
    <description>Packed cells average.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>1st and 5th day , 1st and 6th month after surgical intervention.</time_frame>
    <description>Infections, adverse reactions.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Hip Fracture</condition>
  <condition>Surgical Intervention</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 65 years old

          -  With Hip fracture or peritrochanteric fracture.

          -  Who needs surgical intervention.

          -  And sign the informed consent form.

        Exclusion Criteria:

          -  Tumor pathological fracture.

          -  Two or more long bone fractures.

          -  Seric Ferritin levels &gt; 300 ng/ml.

          -  Hypersensitivity to Iron sucrose or any component of the formulation.

          -  Patients with allogeneic transfusion rejection.

          -  Patients with previous blood transfusion request (Hb&lt; 8g/dl).

          -  Patients treated with hematopoietic growth factors.

          -  Patients with Anticoagulant treatment, due to thromboembolic high risk disease.

          -  Asthma in treatment.

          -  Cirrhosis, Acute Hepatitis, or increased Aminotransferases (&gt; 3 times the upper limit
             of normal).

          -  Advanced Dementia (GDS&gt;5) from the Global Deterioration Scale.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Cruceta, MD</last_name>
    <phone>932279838</phone>
    <email>acruceta@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Domingo, MD</last_name>
    <phone>932279871</phone>
    <email>adomingo@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Servicio de Cirugía Ortopédica y Traumatología. Hospital Clinic.</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Domingo, MD</last_name>
      <phone>932275533</phone>
      <email>adomingo@clinic.ub.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anna Domingo Trepat</name_title>
    <organization>Hospital Clinic</organization>
  </responsible_party>
  <keyword>Intravenous iron sucrose</keyword>
  <keyword>Anemia</keyword>
  <keyword>Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

